Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Hypertension. 2012 Jun 25;60(2):319–325. doi: 10.1161/HYPERTENSIONAHA.112.194787

Figure 3.

Figure 3

Summary data showing changes in fasting plasma glucose (left), HOMA-IR (middle), and serum potassium (K), after 12 weeks of chlorthalidone (Chlor) alone (solid bars), chlorthalidone plus spironolactone (Spiro, hatched bars), and chlorthalidone plus irbesartan (gray bars) compared with baseline (white bars). Data are mean ± SE. * p < 0.01 vs baseline, † p < 0.05 vs chlorthalidone plus spironolactone, ‡ p < 0.01 vs chlorthalidone plus spironolactone.